This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

NCT04762641 · clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
100
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

ABL Bio, Inc.